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Cellular delivery of enzyme-loaded DNA origami†
Ari Ora,‡a Erika Järvihaavisto,‡a Hongbo Zhang,b Henni Auvinen,a Hélder A. Santos,b
Mauri A. Kostiainen*a and Veikko Linko*a
In this communication, we show that active enzymes can be delivered
into HEK293 cells in vitro when they are attached to tubular DNA
origami nanostructures. We use bioluminescent enzymes as a cargo
and monitor their activity from a cell lysate. The results show that the
enzymes stay intact and retain their activity in the transfection
process. The method is highly modular, which makes it a compelling
candidate for a great variety of delivery applications.
In molecular medicine, various materials can be used in creating
applicable drug delivery vehicles, such as metallic nanoparticles,
viruses and polymers.1–3 However, one of the challenges is to
develop carriers and advanced systems that are concurrently safe,
efficient, biocompatible and entirely modular. In this respect,
DNA nanotechnology offers an intriguing approach: fully
programmable, custom-shaped DNA nanostructures4,5 can meet
the prerequisites for smart nanocarriers, and therefore, they
possess a huge potential in diverse biomedical applications.6–8
One of the most convenient techniques to build DNA
nanostructures is to utilize scaffolded DNA origami,9 which
facilitates robust, nanometer-level precise fabrication of arbitrary
DNA shapes.10–13 Moreover, the method has served as an important
starting point for developing user-friendly software for designing
DNA objects14–16 and completely new design strategies for DNA-
based nanoconstruction.17–20 The structural versatility provided
by the DNA origami approach has yielded many intriguing
applications, including optical nanodevices,21 custom-shaped
metal nanoparticles,22–24 and artificial ion channels.25
Recently, there has been a growing interest towards the
nanomedical implementations of the DNA nanotechnology,
such as DNA sensors,26 logic-gated DNA nanorobots for controlling
cell signaling27 and DNA origami structures for circumventing
drug resistance, as well as delivering small anti-cancer drugs into
cells both in vitro and in vivo.28–32 Other examples of DNA-based
delivery systems include cages for transporting siRNA motifs33 and
DNA tubes for CpG-triggered immunostimulation.34 One of the
challenges in cellular transport of DNA-based nanostructures is
their relatively poor transfection rates.35 However, it has been shown
that the transfection can be improved by coating the structures with
virus proteins36 or by introducing DNA intercalators37 that modify
the surface properties of the objects. Furthermore, lipid membrane
encapsulation can significantly increase the pharmacokinetic bio-
availability of the DNA structures and decrease immune activation.38
Therefore, the recent developments in the field prospectively make
DNA origami nanostructures as suitable candidates for smart drug
delivery vehicles and carriers in advanced therapeutics.
In this communication, we show how a DNA origami loaded
with active molecular components can be delivered into cells
(Fig. 1). We employed bioluminescent enzymes as a cargo for
the tubular DNA origami and transfected the formed complex
into cells in vitro. By using these detection-sensitive enzymes,
we were able to demonstrate the activity of the delivered enzymes
from the cell lysate (after transfection) using a luminescence assay.
The assay shows that the enzymes can stay intact in the transfection
process and retain their catalytic activity, thus demonstrating the
feasibility of the proposed delivery system. We believe that the
system presented here can find uses, for example, in enzyme
replacement therapy. Similarly, the modular DNA origami
approach could be used in transporting other pivotal molecules
and complexes into cells, thus enabling highly sophisticated
medical treatments. Loading of the origami can be realized by
attaching molecules via DNA hybridization or by using other
linking techniques, such as avidin–biotin interaction. Furthermore,
encapsulating active enzymes inside hollow origami cages has
recently been demonstrated to efficiently protect the enzymes
against proteolytic degradation.39
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The DNA origami used in this work is a hexagonal tube
(HT)40 (see Fig. 1), and it is equipped with three biotinylated (B)
binding sites on its inner surface. The biotins are assigned for
the avidin-modified cargo (three enzymes should fit in the
cavity of the carrier). The DNA origami structure (hexagonal
tube with biotin = HTB) was assembled as explained previously,40
and after the folding the formed structures were purified by PEG-
purification41 or by spin-filtering in the 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES)/NaOH buffer (6.5 mM
HEPES, pH adjusted to 6.8) (see ESI†). The folded and purified
HTBs were characterized using transmission electron microscopy
(TEM) and agarose gel electrophoresis (see Fig. 2), which revealed
proper folding of the HTBs and the efficient removal of the excess
staple strands from the folding solution.
After purification, HTB origamis were incubated at least 6 h
with the bioluminescent streptavidin-lucia (LUC) luciferase
enzymes (InvivoGen). The enzymes were added in excess amounts,
and the unbound enzymes were removed again by PEG-purification
or by spin-filtering (HEPES/NaOH buffer) (see ESI†). HTB origamis
with LUC-enzymes (LUC + HTB) were also analyzed by gel electro-
phoresis (Fig. 2). Addition of LUC smears the origami band, thus
indicating complexation with origamis (see the LUC + HTB lane
in Fig. 2). After the structural characterization and before the
transfection, the bioluminescence decay kinetics of the fabricated
LUC + HTB, free luciferase (LUC (adjusted)) and bare origami
(HTB) were analyzed (see Fig. 3). The luminescence assay and
analysis are carried out similarly as explained previously;42
briefly, the activity of each sample was characterized by mixing
10 ml of the sample solution with the 50 ml of commercial
coelenterazine-based luminescence assay reagent (QUANTI-Luc,
InvivoGen), and by monitoring the luminescence by luminometer
(BioTek Cytation 3). The resulted luminescence decay as a function
of time is shown in Fig. 3. The concentration of the free luciferase
sample (LUC (adjusted)) was titrated to match the luminescence
decay curve of LUC + HTB sample. Typically, the concentration of
free luciferase (LUC (adjusted)) was 150–600 nM, i.e., 5–15 times
the origami concentration (varied between 10–100 nM). Therefore,
the results indicate that LUC binds not only to biotinylated
strands, but also unspecifically to DNA origami, and that LUC +
HTB sample may contain a modest amount of enzymes that were
Fig. 1 A DNA origami equipped with three biotinylated binding sites (on
the inner surface) is loaded with streptavidin-modified Lucia luciferase
enzymes (LUC). Loaded origamis are transiently transported into cells, and
subsequently, the cells are washed in order to remove free and cell
membrane-bound complexes. Activity of the delivered LUC is measured
from the cell lysates using coelenterazine-based luminescence assay.
Fig. 2 Left: CanDo-simulated14,15 solution shape of the designed DNA
origami40 and TEM images of the structures with corresponding orientations.
The width of the origami is between 27–33 nm and the cavity is 14–21 nm
wide. Right: Agarose gel electrophoresis of the hexagonal tubes with
biotin binding sites (folded and purified HTB) and hexagonal tubes with
LUC-enzymes (LUC + HTB). Structures are electrophoresed after folding
and after PEG-purification, and their running speeds are compared to the
scaffold strand M13mp18 (S). Purification (PEG-based or spin-filtering)
removes practically all the excess staple strands (bright area at the
bottom of the folded HTB lane) and most of the unbound LUC-enzymes
(see also ESI†).
Fig. 3 Enzyme activity and the sample quality were verified before transfection
by the luminescence decay assay. The graph shows typical luminescence decay
as a function of time for a purified DNA origami loaded with luciferases (LUC +
HTB), similar amount of free luciferase (LUC (adjusted)) and an empty
DNA origami (HTB). The concentration in the free luciferase sample is
adjusted to match the decay curve of the LUC + HTB sample. The first data
points were recorded 10 seconds after adding the coelenterazine-based
luminescence assay reagent to the origami solutions. The inset depicts the
statistics of the luminescence assay (relative luminescence intensity): the
maximum luminescence intensity is depicted with 100% in each measurement
and this value was compared to the maximum intensity of the corresponding
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not removed in the purification process (see ESI†). In addition, the
activity of enzymes that are attached to DNA origami have been
found to be higher than that of free enzymes,39 which could also
explain the effect. However, the free LUC sample (used as a control
in the transfection studies) was always adjusted to match LUC + HTB
kinetics before the transfection in order to compensate these effects.
Fully characterized and tested samples (LUC + HTB, LUC
(adjusted) and HTB at B1 nM concentration) were then trans-
fected into HEK293 cells transiently (see ESI† for details of
transfection and cell culturing). To visualize the different
compartments under confocal microscopy, we labeled cell
membrane with Cell Mask Deep Red, HTB origamis with
fluorescent Cy3 dyes (five Cy3-modified strands per each origami)
and LUC with Pacific Blue dye (labeled with Molecular Probes’
Pacific Bluet Protein Labeling Kit) and followed the transfection.
The viability of cells was always verified before imaging. After
12 h of transfection, it was observed that the origamis and
enzymes were found in cells (Fig. 4A and B). The results show
that in some cases LUC and HTB were clearly co-localized
(Fig. 4A), but it also seems that unspecifically bound LUC might
detach from the HTB in the transfection (see ESI†). Moreover,
bare LUC (LUC (adj.)) was transfected to some extent (Fig. 4B).
Furthermore, we also tested longer (36 h) transfection, which
showed that HTB is co-localized with the cell nuclei (see ESI†).
For monitoring the transfection (12 h) and the activity of the
samples via luminescence assay, the cells were washed carefully
3 times with PBS in order to remove the complexes that were
possibly attached to cell membranes or the cell culturing plates.
Cells were lysed using coelenterazine-based substrate and the
bioluminescence was immediately detected as explained above.
The luminescence decay of the samples was significantly slower
in cell lysates than before transfection, presumably due to the
dilution of the samples during the transfection. The slower
kinetics enabled detection of clear differences between the
luminescence intensity levels of each sample within the time-scale
of several minutes. Fig. 4C shows the normalized maximum
luminescence intensities (the maximum intensity in each measure-
ment represents 100% relative luminescence) for the purified LUC +
HTB, LUC (adj.) and bare HTB samples. The results show that
although the activity of LUC + HTB and bare LUC were adjusted
to the same level before transfection (Fig. 3 inset), the LUC +
HTB displays roughly 3 times as high intensity as the free LUC
sample after the transfection (Fig. 4C).
As additional control experiments, we used only the structural
components of the DNA origami (short DNA strands, i.e., staples,
and a long scaffold strand), which we incubated with LUC and
studied how these DNA strands alone could affect the results.
With the purification methods used here, it is impossible
to separate staples and scaffold strands from the excess and
unbound LUC. Nevertheless, we then used the unpurified
samples (containing equal amounts of LUC in each sample,
i.e., 15 times HTB concentration). It was observed that the
luminescence intensity levels were enhanced using the short DNA
staples or the scaffold strand alone. As a result, the luminescence
level of the LUC + staples sample was similar to LUC + HTB but
higher than LUC + scaffold and clearly higher than bare LUC. All
the abovementioned experiments were performed without any
transfection reagent, but as a control, we also carried out the
experiments with a common transfection reagent polyethylenimine
(PEI, B25 kDa, linear). As expected, PEI can enhance the
transfection. The data from the controls and the samples
transfected with PEI are presented in ESI.† Overall, all the
results prove the feasibility of the proposed method, since the
DNA origami working concentrations could be as low as 500 pM.
In conclusion, we have demonstrated how a designer DNA
origami loaded with functional cargo (in principle any streptavidin-
or biotin-modified cargo) can be transported into cells. In general,
the cellular delivery of functional proteins is essential in molecular
medicine, therapeutics and nanomedical engineering.43–49 Here, the
proof-of-principle delivery works with or without the transfection
Fig. 4 (A and B) Confocal micrographs of LUC + HTB (A) and LUC (adjusted) without HTB (B) samples after 12 h transfection without PEI: LUC is labeled
with Pacific Blue dye (blue), HTB with Cy3-modified strands (green) and cell membrane by cell mask deep red (red). (C) The statistics of the luminescence
assay (relative luminescence intensity) measured from the cell lysate (without PEI): the maximum luminescence intensity corresponds 100% in each
sample set (LUC + HTB sample showed always the highest activity, and this value was compared to the maximum intensity of the corresponding LUC
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reagent and without any surface functionalization. Therefore,
we strongly believe that the transfection properties could be
significantly enhanced by introducing specified cell targeting
ligands, surface modulations and by further taking advantage of
the structural modularity of DNA origami.36–38,50 Recently, it
was shown that DNA-coated enzymes can transfect efficiently
and retain their activity in cells.51 Further, encapsulation or
anchoring enzymes using DNA origami structures could protect
enzymes against protease digestion,39 which can lead to interesting
implementations in nanomedicine. Recently, it has also been
demonstrated that reaction rates of the enzyme-loaded origamis
can be controlled by coating the origamis with synthetic polymers.42
Thus, this work further intensifies the development of smart and
tailored nanocarrier systems that are able to facilitate a plethora of
biomedical applications in the near future.
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